SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks 
Airbus CEO Warns Staff to Prepare for Rising Geopolitical Risks Amid Trade Tensions 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Exxon Mobil’s XTO Energy Explores Sale of Eagle Ford Shale Assets in South Texas 
Winter Storm Triggers Widespread Flight Cancellations Across U.S. as Airlines Urge Travelers to Rebook 
U.S. Lawmakers Demand Scrutiny of TikTok-ByteDance Deal Amid National Security Concerns 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
SEC Drops Gemini Enforcement Case After Full Repayment to Earn Investors 
Embraer Targets Growth as Regional Jet Demand Surges Post-Pandemic 
Tesla Plans FSD Subscription Price Hikes as Autonomous Capabilities Advance 
FCC Chairman Raises Competition Concerns Over Netflix–Warner Bros. Discovery Deal 
Hermès Menswear Marks Historic Transition as Véronique Nichanian Bids Farewell in Paris 
Nintendo Stock Jumps as Switch 2 Becomes Best-Selling Console in the U.S. in 2025 
CN Energy Group Inc. Stock Slides After Nasdaq Delisting Notice Over Bid Price Rule 
Baker Hughes Reports 11% Rise in Q4 Adjusted Profit Driven by LNG Demand 
Microsoft Restores Microsoft 365 Services After Widespread Outage 
Delta Air Lines Operates Reduced Flight Schedule as Winter Storm Disrupts U.S. Travel 
ROCKVILLE, Md., May 10, 2017 -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will participate in the Gene Therapy and Gene Editing panel discussion at the Bank of America Merrill Lynch 2017 Health Care Conference on Wednesday, May 17, 2017 at 1:40 p.m. PT at the Encore Wynn in Las Vegas, NV. In addition, REGENXBIO senior management will be holding one-on-one meetings at the conference.
About REGENXBIO
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO’s NAV® Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.
CONTACT: Investors Heather Savelle, 646-395-3734 [email protected] Media Adam Pawluk, 202-591-4063 [email protected]
